Educational Course

Medical Weight Management

A practical exam app based on the 2025 ACC concise clinical guidance on medical weight management for optimizing cardiovascular health.

Course progress 0%

Start Here

What learners will be able to do

Learner registration

Enter the learner's information before starting. Results are stored in this browser and can be exported for upload to a roster or LMS.

Frame obesity clinically

Recognize obesity as a chronic disease with direct cardiovascular implications, not a simple lifestyle failure.

Select candidates thoughtfully

Use BMI, anthropometrics, excess adiposity, weight-related consequences, contraindications, and patient goals.

Manage longitudinally

Plan dose titration, side effect monitoring, medication de-escalation, multidisciplinary support, and long-term therapy.

Source basis: This app is adapted for education from the 2025 ACC expert consensus statement on medical weight management for optimization of cardiovascular health. It is educational only and is not a diagnostic device, prescribing tool, coverage determination, or substitute for clinician judgment, local policy, or the full guideline.
1RiskObesity, CVD, HFpEF, ASCVD, AF, OSA, T2DM, and metabolic disease.
2DiagnosisBMI limitations, waist measures, adiposity, race-specific thresholds, and eligibility.
3TherapyNuSH therapies, GLP-1, GIP, semaglutide, tirzepatide, titration, and contraindications.
4MonitorComorbidity adjustments, GI effects, AKI risk, de-escalation, and follow-up.
5CareStigma reduction, team-based care, access barriers, and long-term maintenance.

Module 1

Obesity is a cardiovascular disease driver

The ACC document frames obesity as a chronic disease with cardiovascular implications. Obesity increases risk through hemodynamic, inflammatory, metabolic, functional, and structural pathways.

  • Obesity is associated with heart failure, coronary artery disease, stroke, atrial fibrillation, sudden cardiac death, venous thromboembolism, and valvular disease.
  • It contributes to cardiovascular risk factors including type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and physical inactivity.
  • Weight loss thresholds matter: about 5% can improve risk factors, while larger losses may be needed for obesity-related comorbidity and cardiovascular outcome improvement.
  • The cardiovascular community is encouraged to engage directly in obesity treatment because the disease is common and affects cardiovascular outcomes.

Clinical frame

Not: a willpower problem.

Yes: a chronic disease influenced by genetics, neurohormonal pathways, psychology, social determinants, medications, medical conditions, and environment.

Knowledge check

Which statement best reflects the paper's framing?

Module 2

Diagnosis and eligibility require more than a number

Measure
What it adds
Limitation
BMI
Useful population-level weight category and common eligibility anchor.
Does not fully account for adiposity, fat distribution, sex, race, or muscle mass.
Waist circumference
Identifies central adiposity and cardiometabolic risk.
Thresholds differ by population and need consistent clinical use.
Waist-to-height ratio
Can help identify central adiposity across body sizes.
Requires broader implementation and interpretation.
Clinical consequences
Links weight to impaired organ function, functional status, CVD risk, OSA, T2DM, MASLD, and HFpEF.
Requires individualized assessment.
The document notes that BMI thresholds can differ by ancestry. For example, lower BMI cut points may be appropriate for South Asian and Chinese populations because health risk can occur at lower BMI values.
MeasureBMI plus adiposity markers
StageOrgan and functional consequences
ScreenContraindications and pregnancy plans
PlanGoals, access, side effects, follow-up

Module 3

NuSH therapies and medication choice

What NuSH means

Nutrient-stimulated hormone therapies act on metabolic and appetite pathways. In this guidance, the category includes GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists.

Preferred options

Semaglutide and tirzepatide are described as the obesity medications of choice among current NuSH therapies because of higher efficacy and outcome evidence.

Practical selection

Insurance coverage, availability, affordability, adverse effects, contraindications, and patient preference often determine which agent can actually be used.

LiraglutideDaily GLP-1 receptor agonist with lower average weight loss than newer weekly agents.
SemaglutideWeekly GLP-1 receptor agonist with strong weight loss and cardiovascular outcome evidence.
TirzepatideWeekly dual GLP-1/GIP agonist with high average weight loss; cardiovascular outcome data continue to evolve.

Knowledge check

Which statement best describes NuSH therapies?

Module 4

Comorbidities, side effects, and monitoring

Monitor common effects

GI symptoms such as nausea, diarrhea, vomiting, abdominal pain, and constipation are common. Dose reduction, slower titration, hydration, and behavioral strategies may help.

Adjust related therapies

As weight and cardiometabolic status improve, antihypertensives, diuretics, diabetes medications, CPAP settings, thyroid dosing, anticoagulants, or other weight-based medications may need reassessment.

Avoid unsafe shortcuts

The document discourages compounded NuSH therapies because of dosing error and counterfeit or impurity concerns.

GI side effectsSlow or reduce dose
Low BP or volume lossReassess antihypertensives or diuretics
Diabetes medsReduce hypoglycemia risk
Pregnancy planningStop weekly agents in advance
Long-term obesity treatment is usually the default plan. Stopping medication commonly leads to weight regain unless the patient and clinician decide otherwise.

Module 5

Patient-centered, team-based obesity care

The guidance emphasizes that obesity care should be respectful, longitudinal, multidisciplinary, and realistic about access. Patients need evidence-based treatment, not blame.

  • Use person-first language and design spaces with appropriate chairs, gowns, scales, cuffs, exam tables, and imaging/procedure capacity.
  • Initial visits should identify contributors, consequences, contraindications, anthropometrics, goals, and treatment preferences.
  • More frequent contact can improve weight loss and maintenance, especially during titration and early follow-up.
  • Team members may include clinicians, pharmacists, registered dietitians, behavioral therapists, and exercise physiologists.
  • Access barriers are real; cost and coverage influence medication choice and can push patients toward unsafe unregulated options.

Care goal

Not just a scale number. Goals can include cardiometabolic risk reduction, quality of life, functional status, sleep apnea improvement, HFpEF symptom improvement, and psychosocial health.

StartDiagnose, stage, and set goals
TitrateMonitor response and side effects
AssessLook for at least 5% weight loss early
MaintainContinue therapy and lifestyle supports
CoordinateAdjust comorbidity treatments

Final Exam

Check understanding

Passing score is 80%. A printable credential appears after a passing attempt.

Certificate of Completion

Medical Weight Management Exam App

This certifies that

Learner

completed the course exam with a passing score.

ID-
Score-
Date-

Saved results in this browser

LearnerIDScoreStatusDate